Home News Industry News

Curaleaf Responds to FDA Letter

Industry News

Curaleaf Responds to FDA Letter

The leading vertically integrated cannabis operator in the United States, today issued the following statement in response to a letter from the U.S. Food and Drug Administration ("FDA") regarding its CBD product marketing: Curaleaf is committed to the highest standards of quality and compliance, and will work collaboratively with the FDA to resolve all issues addressed in the agency's letter. The Company will respond to the FDA letter within the required 15 working days. Compliance is a top priority for Curaleaf and the Company is fully committed to complying with FDA requirements for all of the products that it markets. We can affirm that nothing in the letter raises any issues concerning the quality and consistency of any Curaleaf product or calls into question the high safety standards of the Company's cultivation and manufacturing processes. Curaleaf CBD products are all derived from hemp and meet the requirements of the Farm Bill. About Curaleaf Holdings 
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 48 dispensaries, 13 cultivation sites and 12 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as in the CBD category through its Curaleaf Hemp brand and Bido brand for pets. Investor Contact: 
Dan Foley, VP, Finance and Investor Relations 
IR@Curaleaf.com  Media Contact: 
Megan Bishop, SVP
Media@Curaleaf.com

 

Share

 

Other news